STOCK TITAN
  1. Home
  2. News
  3. VERV

Verve Therapeutics Inc - VERV STOCK NEWS

Welcome to our dedicated news page for Verve Therapeutics (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Verve Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Verve Therapeutics's position in the market.

News
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Verve Therapeutics, Inc. has made significant progress in developing single-course gene editing medicines for cardiovascular disease, with FDA clearing its Investigational New Drug Application for VERVE-101 in HeFH patients. Verve also announced an expanded collaboration with Eli Lilly and Company and the acquisition of product rights to Verve's PCSK9 and ANGPTL3 programs. The company reported $485.2 million in cash, cash equivalents, and marketable securities, ensuring cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.83%
Tags
earnings
-
News
Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
Rhea-AI Summary
Verve Therapeutics has announced that Eli Lilly and Company (Lilly) has acquired certain product rights to Verve's cardiovascular gene editing programs from Beam Therapeutics. The product candidates are designed to lower low-density lipoprotein cholesterol in patients with or at risk for cardiovascular disease. Lilly now holds the product rights previously held by Beam, including the right to opt-in to share development expenses and to jointly commercialize the products in the United States. Verve retains control of development and commercialization outside the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.95%
Tags
none
-
News
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
Rhea-AI Summary
Verve Therapeutics receives FDA clearance to conduct clinical trial for cardiovascular disease treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
none
News
Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023
Rhea-AI Summary
Verve Therapeutics to present interim data from its heart-1 Phase 1b clinical trial of VERVE-101 at AHA Scientific Sessions 2023. VERVE-101 aims to reduce LDL cholesterol. Investor event to be held on November 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.75%
Tags
conferences clinical trial
-
News
Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Rhea-AI Summary
Verve Therapeutics CEO to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
conferences
-
News
Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
Rhea-AI Summary
Verve Therapeutics appoints Fred Fiedorek as CMO, Andrew Bellinger transitions to CSO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
management
News
Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Verve Therapeutics, Inc. reported recent company progress and financial results for the second quarter of 2023. Their primary focus is on developing medicines targeting three pillars of cardiovascular risk: low-density lipoproteins (LDL), triglyceride-rich lipoproteins (TRL) and lipoprotein(a) (Lp(a)). They are expecting to report initial clinical data from the heart-1 Phase 1b clinical trial of VERVE-101 in the fourth quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
earnings
-
News
Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences
-
News
Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease
Rhea-AI Summary
Verve Therapeutics announces exclusive research collaboration with Eli Lilly and Company to advance its gene editing program targeting lipoprotein(a) (Lp(a)). Verve will receive $60 million upfront payment and equity investment. Verve has opt-in rights to co-fund and share in potential margins of products resulting from the collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.02%
Tags
none
News
Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
conferences
Stock VERV logo
Verve Therapeutics Inc

Nasdaq:VERV

VERV Rankings

#2844 Ranked by Market Cap
#5259 Ranked by Stock Gains
N/A Ranked by Dividends

VERV Stock Data

635.51M
66.88M
7.65%
88.06%
18.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Cambridge

About VERV

verve therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. the company brings together human genetics analysis and gene editing – two of the biggest breakthroughs in 21st century biomedicine – to develop transformative therapies for coronary heart disease. verve is developing medicines, administered once in life, to safely edit the genome of adults to permanently lower ldl cholesterol and triglyceride levels and thereby treat coronary heart disease. founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, verve is backed by a top-tier syndicate of investors, including gv (formerly google ventures), arch venture partners, f-prime capital, biomatics capital, wellington management, casdin capital, and partners innovation fund. the company was recognized as a "2020 best places to work" by the boston business journal. verve is headquartered in cambridge, massachusetts.